Interesting to note that the AGM has been pushed back to after our delisting and the three presentations at the SNO conference.
SNO Annual Meeting (Vancouver, Canada)
Title: Phase 1 study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations: pilot analysis of circulating tumor DNA for patient eligibility confirmation and post treatment response Presenter: Brandon S. Imber (Memorial Sloan Kettering Cancer Center, New York)
Date: Friday, 17 November 2023
Type: Poster Presentation
SNO Annual Meeting (Vancouver, Canada)
Title: Combining ONC201 and paxalisib for the treatment of Diffuse Midline Glioma (DIPG); the preclinical results underpinning the international Phase II clinical trial (NCT05009992)
Presenter: Evangeline R. Jackson (University of Newcastle, Australia)
Date: Friday, 17 November 2023
Type: Plenary Oral Presentation
SNO Annual Meeting (Vancouver, Canada)
Title: PNOC022: A combination therapy trial using an adaptive platform design for patients with Diffuse Midline Gliomas (DMGs) at initial diagnosis, post-radiation therapy and at time of Progression
Presenter: Sabine Mueller (University of California, San Francisco)
Date: Sunday, 19 November 2023
Type: Oral Presentation
- Forums
- ASX - By Stock
- KZA
- Ann: Change of AGM date
Ann: Change of AGM date, page-2
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)